比较ABC-14方案(阿扎胞苷、维奈克拉和西达本胺)与传统「3+7」强化诱导方案或AB-14方案(维奈克拉联合阿扎胞苷)在新诊断急性髓系白血病中的疗效与安全性:一项前瞻性、多中心、随机、开放标签临床试验的研究方案
本研究为前瞻性、多中心、随机、开放标签临床试验,将新诊断急性髓系白血病患者按是否适合强化化疗分层为不适合强化化疗组和适合强化化疗组,分别随机接受ABC-14与AB-14方案或ABC-14与「3+7」方案,主要终点为复合完全缓解率。研究旨在证明ABC-14方案在诱导治疗中不劣于「3+7」方案,同时克服AB方案耐药并降低「3+7」方案相关毒性。
要点
- 不适合强化化疗者随机接受ABC-14或AB-14方案,适合强化化疗者随机接受ABC-14或「3+7」方案。
- 主要终点为复合完全缓解率(CRc),次要终点包括MRD阴性率、缓解持续时间、1年无复发生存率和1年总生存率。
- 探索性终点包括ABC-14组遗传特征谱、住院时长、治疗费用、血制品输注量、生活质量和凋亡指数。
核心结论
- 本研究旨在证明ABC-14方案在新诊断急性髓系白血病诱导治疗中不劣于「3+7」方案,同时克服AB方案耐药并降低「3+7」方案相关毒性,为急性髓系白血病提供广泛适用的替代诱导策略。
研究设计与样本
- 前瞻性、多中心、随机、开放标签临床试验,将新诊断急性髓系白血病患者按是否适合强化化疗分层为不适合强化化疗组和适合强化化疗组。
- 不适合强化化疗组随机接受ABC-14或AB-14方案,适合强化化疗组随机接受ABC-14或「3+7」方案。
- 试验注册于ClinicalTrials.gov,注册号NCT06451861,注册日期2024年6月11日。
关键数值与推荐
- 主要终点为复合完全缓解率(CRc)。
- 次要终点包括可测量残留病(MRD)阴性率、缓解持续时间(DoR)、1年无复发生存(RFS)率和1年总生存(OS)率。
- 探索性终点包括ABC-14组的遗传特征谱、住院时长、治疗费用、血制品输注量、生活质量和凋亡指数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Induction therapy is the first critical step in the overall treatment of Acute myeloid leukemia (AML). The "3 + 7" regimen remains the backbone treatment for newly diagnosed AML patients suitable for intense chemotherapy (IC). However, its efficacy, toxicity, high complications management costs, and prolonged hospitalizations necessitate optimization. The azacitidine-venetoclax (AB) regimen is recommended for elderly or IC-ineligible AML patients, but its efficacy and safety remain suboptimal regarding early mortality and specific leukemia subtypes (e.g., M5, RUNX1-, FLT3-ITD-, TP53-mutated AML, or cases with high MCL-1 expression). Chidamide, a novel oral histone deacetylase inhibitor, counteracts venetoclax-induced MCL-1 upregulation and synergizes with azacitidine-venetoclax to induce AML cell apoptosis. Whether the Azacitidine, Venetoclax, and Chidamide (ABC) regimen can match the "3 + 7" or AB regimen in newly diagnosed AML induction therapy warrants investigation. METHODS: Newly diagnosed AML patients will be stratified by IC suitability into unfit-AML and fit-AML. Unfit-AML patients will be randomized to receive ABC-14 or AB-14 regimens. Fit-AML patients will be randomized to receive ABC-14 or "3 + 7" regimens. The primary endpoint is composite complete response rate (CRc). Secondary endpoints include the measurable residual disease (MRD) negative rate, duration of remission (DoR), 1-year Relapsed-free survival (RFS) rate, 1-year overall survival (OS) rate. Exploratory endpoints include the genetic characteristics spectrum of the ABC-14 group, hospital stay duration, treatment costs, blood product transfusion volume, quality of life, and apoptotic index. DISCUSSION: This study aims to demonstrate that ABC-14 regimen is non-inferior to "3 + 7" regimen in newly diagnosed AML induction therapy while overcoming AB resistance and reducing toxicity associated with "3 + 7". It seeks to provide a broadly applicable alternative induction strategy for AML. TRIAL REGISTRATION: ClinicalTrials.gov NCT06451861, Registered on June 11, 2024. https://clinicaltrials.gov/study/NCT06451861 .
引用
- Yan H, Huang X, Wu P, et al. Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional "3 + 7" intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial. Trials. 2025. PMID: 41366419. doi:10.1186/s13063-025-09339-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。